Evidence map›Paper›PMID 36824014›Full record

ArticleESC heart failure2023

The interaction between physical frailty and prognostic impact of heart failure medication in elderly patients.

Takuro Abe, Kentaro Jujo, Daichi Maeda, Katsumi Saito, Yuki Ogasahara, Kazuya Saito, Hiroshi Saito, Kentaro Iwata, Masaaki Konishi, Takeshi Kitai and 11 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESC heart failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. High-intensity care for GDMT titration.Heart failure reviews · 2024
    Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 9 institutions in 1 country.

Takuro AbeDepartment of Cardiology, Nishiarai Heart Center Hospital, 1-12-8 Nishiarai-Honcho, Adachi-ku, Tokyo, 123-0845, Japan.
Kentaro JujoDepartment of Cardiology, Nishiarai Heart Center Hospital, 1-12-8 Nishiarai-Honcho, Adachi-ku, Tokyo, 123-0845, Japan.ORCID 0000-0002-2011-8204
Daichi MaedaDepartment of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Katsumi SaitoDepartment of Cardiology, Nishiarai Heart Center Hospital, 1-12-8 Nishiarai-Honcho, Adachi-ku, Tokyo, 123-0845, Japan.
Yuki OgasaharaDepartment of Nursing, The Sakakibara Heart Institute of Okayama, Okayama, Japan.
Kazuya SaitoDepartment of Rehabilitation, The Sakakibara Heart Institute of Okayama, Okayama, Japan.
Hiroshi SaitoDepartment of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Kentaro IwataDepartment of Rehabilitation, Kobe City Medical Center General Hospital, Kobe, Japan.
Masaaki KonishiDivision of Cardiology, Yokohama City University Medical Center, Yokohama, Japan.
Takeshi KitaiDepartment of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe, Japan.
Takatoshi KasaiDepartment of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Hiroshi WadaDepartment of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical University, Shimotsuke, Japan.
Shin-Ichi MomomuraSaitama Citizens Medical Center, Saitama, Japan.
Nobuyuki KagiyamaDepartment of Digital Health and Telemedicine R&D, Juntendo University, Tokyo, Japan.
Kentaro KamiyaDepartment of Rehabilitation, Kitasato University School of Allied Health Sciences, Sagamihara, Japan.
Masashi YamashitaDepartment of Rehabilitation Sciences, Graduate School of Medical Sciences, Kitasato University, Sagamihara, Japan.
Nobuaki HamazakiDepartment of Rehabilitation, Kitasato University Hospital, Sagamihara, Japan.
Kohei NozakiDepartment of Rehabilitation, Kitasato University Hospital, Sagamihara, Japan.
Emi MaekawaDepartment of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan.
Junya AkoDepartment of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan.
Yuya MatsueDepartment of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Juntendo University · JPKitasato University · JPMirai Hospital · JPKitasato University Hospital · JPKobe City Medical Center General Hospital · JPHiroshima City Asa Citizens Hospital · JPJichi Medical University · JPSakakibara Hospital · JPYokohama City University Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsFrailty is highly prevalent and associated with poor prognoses in elderly patients with heart failure (HF). However, the potential effects of physical frailty on the benefits of HF medications in elderly patients with HF are unclear. We aimed to determine the influence of physical frailty on the prognosis of HF medications in elderly patients with HF with reduced and mildly reduced ejection fraction (HFr/mrEF). METHODS AND

resultsFrom the combined HF database of the FRAGILE-HF and Kitasato cohorts, hospitalized HF patients with a left ventricular ejection fraction < 50% and age ≥ 65 years were analysed. Patients treated with or without renin-angiotensin-aldosterone system inhibitors (RAASi) and beta-blockers at discharge were compared. Physical frailty was defined by the presence of ≥3 items on the Japanese version of the Cardiovascular Health Study criteria. The primary endpoint was all-cause mortality rate. Among the 1021 enrolled patients, 604 patients (59%) received both RAASi and beta-blockers, and 604 patients (59%) were diagnosed as physically frail. Patients receiving both RAASi and beta-blockers showed a significantly lower 1 year mortality than those not receiving either, even after adjusting for covariates (hazard ratio: 0.50, 95% confidence interval: 0.34-0.75). This beneficial effect of both medications on 1 year mortality was comparable between patients with and without physical frailty (hazard ratio: 0.53 and 0.51, respectively; P for interaction = 0.77).

conclusionsThe presence of physical frailty did not interact with the beneficial prognostic impact of RAASi and beta-blocker combination therapy in elderly patients with HFr/mrEF.

Indexed as

FrailtyHeart FailureAdrenergic beta-AntagonistsAgedHumansPrognosisStroke VolumeVentricular Function, LeftAdrenergic beta-AntagonistsElderly patientsFrailtyHeart failureHeart failure medicationsPhysical frailty

Identifiers

PMID36824014
PMCPMC10192227
OpenAlexW4321748266

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.